Lots more kids than 400,They did thousands of kids in these studies. 18,000.

[Guest guest]

Wed, 27 Apr 2005 11:58:13 +0200

 

" Sepp Hasslberger " <sepp

 

 

 

Re: Lots more kids than 400, They did thousands of kids in

these studies. 18,000.

 

Re: Lots more kids than 400,

They did thousands of kids in these studies. 18,000

They did thousands of kids in these studies. 18,000

They did thousands of kids in these studies. 18,000

They did thousands of kids in these studies. 18,000

They did thousands of kids in these studies. 18,000

 

 

Thank you ,

 

that is an interesting announcement and shows that they are " feeling

the pressure " . Eighty million for further studies is hardly peanuts.

 

It seems that even our sparse efforts with an article here and there

can put them under obligation to throw some more money at the problem

(the problem of course being that not everyone buys their propaganda

about HIV and the antiretrovirals).

 

Sending a copy to a few activists and interested people.

 

Kind regards

Sepp

 

 

>Hi Sepp, They did thousands of kids in these studies. 18,000

>

>December 22. 1999

>

>http://www.nih.gov/news/pr/dec99/niaid-22.htm

>

>NIAID Renews Funding for the Adult AIDS Clinical Trials Group

>The National Institute of Allergy and Infectious Diseases (NIAID)

>has renewed funding for the Adult AIDS Clinical Trials Group

>(AACTG), the largest clinical trials network in the world. Under the

>new award, the AACTG will receive $80 million in the first year of a

>five-year grant. The funding enables the network to continue

>conducting studies of antiviral interventions, methods to

>reconstitute the immune system damaged by HIV, and the treatment and

>prevention of opportunistic diseases and other HIV-related

>complications.

> " Since the beginning of the AIDS epidemic, the AACTG has made

>enormous contributions in helping people with HIV live dramatically

>longer and healthier lives, " says NIAID Director Anthony S. Fauci,

>M.D. " AACTG studies have been and will continue to be an invaluable

>source of scientific data, significantly advancing our ability to

>treat HIV. "

>The AACTG consists of a Coordinating and Operations Center,

>Statistical and Data Analysis Center and 32 AIDS Clinical Trials

>Units across the country, including new sites in Texas, Tennessee,

>Pennsylvania, Rhode Island and New York. Chair Robert T. Schooley,

>M.D., and Vice Chair Constance A. Benson, M.D., of the University of

>Colorado Health Sciences Center in Denver, will continue to provide

>the group's executive leadership. Victor DeGruttola, Sc.D., of the

>Harvard School of Public Health in Boston, will continue to direct

>the Statistical and Data Analysis Center.

> " With a very strong group of internationally recognized and

>dedicated HIV researchers, the AACTG has remained on the cutting

>edge of HIV therapeutics and responded rapidly to new scientific

>opportunities, " says Dr. Schooley. Acknowledging the AACTG's

>effectiveness in turning laboratory discoveries into new

>intervention strategies at the bedside, peer reviewers rated the

>network as " outstanding. " From its start in 1987, the AACTG has

>played a pivotal role in defining the standard of care for adults

>infected with HIV. AACTG trials have evolved from early studies with

>single-drug regimens to the current drug " cocktails " that make up

>highly active antiretroviral therapy, or HAART. Other recent AACTG

>studies have

>- shown how new combinations of drug regimens can help people who

>have responded poorly to or exhausted other approaches;

>- proven the value of HIV-1 RNA levels in the blood as markers of

>how far the disease has progressed and how beneficial treatments

>have been;

>- identified the significance of antiretroviral drug resistance and

>the reservoirs where HIV remains impervious to treatment;

>- contributed to the understanding of how HIV destroys immune

>function and how the immune system can be restored following HAART;

>- identified regimens for treating and preventing opportunistic

>infections; and

>- improved access to clinical trials for women and underrepresented

>populations within the network's academic and community-based

>clinical trials units.

 

>Among the future priorities for the AACTG are defining the most

>effective antiretroviral treatment strategies at each stage of HIV

>infection, developing new ways to prevent or treat opportunistic

>infections, and focusing on the growing problem of hepatitis C

>co-infection with HIV disease. Researchers also will study the

>interaction between various anti-HIV drugs and seek to lessen

>metabolic abnormalities and other side effects associated with HAART.

>Developing strategies to eliminate reservoirs where HIV lingers

>within the body will be another important focus. Network clinicians

>will explore new approaches to augment the immune system in the

>presence of HIV and will examine promising leads into restoring

>immune function. The long-term effects of anti-HIV therapeutics will

>be further scrutinized as the AACTG seeks to improve patients'

>abilities to tolerate these therapies.

>Press release, fact sheets and other NIAID materials are available

>on the NIAID web site at www.niaid.nih.gov.

>

>Background

>The AACTG is an outgrowth of NIAID's first major program to evaluate

>potential treatments for people with AIDS, which began in the summer

>of 1986. In 1996, the original AIDS Clinical Trials Group branched

>into two separate programs, the Adult AIDS Clinical Trials Group and

>the Pediatric AIDS Clinical Trials Group (PACTG). Since 1986, more

>than 50,000 volunteers have enrolled in AACTG studies, and almost

>18,000 children and pregnant women have participated in PACTG

>studies.

 

>NIAID supports a broad program in HIV therapeutic research. This

>ranges from basic laboratory science to bench-to-bedside studies,

>which test new approaches in small numbers of people, to larger

>clinical trials that recruit patients throughout the country to

>evaluate the best new ways to treat and manage HIV disease. In

>addition to the AACTG and the PACTG, other NIAID-sponsored

>therapeutic research programs include the Acute Infection and Early

>Disease Research Program, the Terry Beirn Community Program for

>Clinical Research on AIDS, and the Integrated Preclinical/Clinical

>Therapeutics Research Program.

>http://www.nih.gov/news/pr/dec99/niaid-22.htm

 

 

--

 

 

The individual is supreme and finds its way through intuition.

 

Sepp Hasslberger

 

 

My page on physics, new energy, economy: http://www.hasslberger.com/

 

Critical perspective on Health: http://www.newmediaexplorer.org/sepp/

 

Antiprohibition and cannabis: http://www.unsaccodicanapa.com/

 

Communication Agents: http://www.communicationagents.com/

 

Freedom of choice - La Leva di Archimede: http://www.laleva.cc/

La Leva's news: http://www.laleva.org/

 

Robin Good - http://www.masternewmedia.org/

 

Trash Your Television! - http://www.tvturnoff.org/

 

Not satisfied with news from the tube and other controlled media?

Search the net! There are thousands of information sources

out there. Start with

 

http://www.whatreallyhappened.com/

http://www.truthout.org/

http://www.joevialls.co.uk/

http://www.Rense.com/